4D Molecular Therapeutics скачать в хорошем качестве

4D Molecular Therapeutics

David Kirn, M.D., Chairman, CEO and Co-Founder Emeryville, CA (Private) 4D Molecular Therapeutics (4DMT) is focused on the discovery and development of targeted and proprietary AAV gene therapy vectors and therapeutic products. The company’s robust discovery platform, termed Therapeutic Vector Evolution, empowers 4DMT to create customized gene delivery vehicles to deliver genes to any tissue or organ in the body, by optimal clinical routes of administration and with resistance to pre-existing antibodies. These proprietary and targeted products allow the company to treat both rare genetic diseases and complex large market diseases. 4DMT is creating a diverse and deep product pipeline through partnerships, while progressing internal 4DMT products toward clinical trials in parallel. 4DMT’s partners include: Pfizer, Roche, uniQure, AGTC and Benitec. 4DMT’s lead product is for the treatment of choroideremia, an inherited retinal disease. www.4dmoleculartherapeutics.com